51.55
+4.29%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Enliven Therapeutics
From its filings with the US Securities and Exchange Commission
Enliven Therapeutics is based in Burlingame, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ELVN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $103.7m. At that date it held total assets of $476.2m and shareholders' equity of $459.6m.
We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. We aim to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Our discovery process combines deep insights into clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs. By combining clinically validated targets and specific target product profiles with disciplined clinical trial design and regulatory strategy, we aim to develop drugs that address unmet needs with an increased probability of clinical and commercial success. Validated targets are those whose role in disease pathology have been demonstrated by mechanistic and clinical studies. We are currently advancing ELVN-001 as well as pursuing multiple additional research-stage opportunities that align with our small molecule development approach.
ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region – Abelson (“BCR-ABL”) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (“CML”). It is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI), meaning it competes with ATP for binding at the kinase active site, thereby blocking phosphorylation and downstream oncogenic signaling.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Mar 2020
- Employees
- 60
- Website
- enliventherapeutics.com ↗
- Head office
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Dr. Richard HeymanNon-Executive Independent Chairman of the Board$353,138
- Mr. Sam KintzPresident, Chief Executive Officer, Director, since 2023$5.5m
- Mr. Benjamin HohlChief Financial Officer, Head of Corporate Development$567,140
- Mr. Anish PatelChief Operating Officer
- Dr. Joseph LyssikatosChief Scientific Officer, since 2023$2.7m
- Dr. Helen CollinsChief Medical Officer$2.8m
- Dr. Rahul BallalDirector, since 2018$284,890
- Mr. Jacob BauerIndependent Director$304,890
- Dr. Mika DerynckIndependent Director$296,390
- Mr. Rishi GuptaIndependent Director$306,140
- Dr. Lori KunkelIndependent Director$533,368
- Mr. Andrew PhillipsIndependent Director$300,390
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 43
- Social
- 58
- Governance
- 24
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Enliven Therapeutics focuses on precision oncology with two lead product candidates ELVN-001 and ELVN-002.
- ELVN-001 targets BCR-ABL gene fusion for chronic myeloid leukemia treatment.
- ELVN-002 targets HER2 mutations including Exon 20 insertion in non-small cell lung cancer.
Weaknesses
- Enliven Therapeutics has only 6 full-time employees as of the latest data.
- The company is a clinical stage firm with no approved products yet.
- The firm's IPO occurred on March 12, 2020, indicating early development stage.
Opportunities
- The precision oncology market shows growth potential for targeted therapies like ELVN-001 and ELVN-002.
- Addressing unmet needs in chronic myeloid leukemia and NSCLC offers significant market opportunities.
- Advancing multiple product candidates provides diversified research opportunities.
Threats
- The clinical stage development of ELVN-001 and ELVN-002 faces regulatory approval risks.
- Competition in oncology therapeutics remains intense despite focused approach.
- Market acceptance of new therapies depends on clinical trial outcomes and pricing pressures.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.